COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
Proxalutamide study #3 of 3
3/10 Late treatment study
Cadegiani et al., Press Conference (Preprint)
The Proxa-Rescue AndroCoV Trial
Source   PDF   Share   Tweet
RCT 590 hospitalized patients, 294 treated with proxalutamide showing significantly lower mortality and faster recovery.

Cadegiani et al., 3/10/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, baseline oxygen requirements 97.0%, 5 authors.
risk of death, 91.4% lower, RR 0.09, p < 0.001, treatment 12 of 294 (4.1%), control 141 of 296 (47.6%).
risk of mechanical ventilation, 91.6% lower, RR 0.08, p < 0.001, treatment 13 of 294 (4.4%), control 156 of 296 (52.7%).
recovery time, 84.2% lower, relative time 0.16, treatment 294, control 296.
hospitalization time, 64.3% lower, relative time 0.36, treatment 294, control 296.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All 3 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images